Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Corvus Pharmaceuticals, Inc.

Market Cap 94Cr 81Cr 75Cr 70Cr 130.72Cr 8.94TCr 133.65Cr 889.6Cr 345Cr 4.33TCr 352.28Cr 344.71Cr 15TCr P/E Ratio 2026 *
-16.4x
P/E Ratio 2027 * -13.1x
Enterprise Value 74Cr 64Cr 59Cr 55Cr 102.46Cr 7.01TCr 104.76Cr 697.27Cr 270.41Cr 3.39TCr 276.11Cr 270.19Cr 12TCr EV / Sales 2026 *
-
EV / Sales 2027 * 114x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
1 day-0.09%
1 week-3.79%
Current month-10.07%
1 month-28.23%
3 months-33.49%
6 months+31.45%
Current year+44.94%
1 week 10.83
Extreme 10.83
11.99
1 month 10.83
Extreme 10.83
16.14
Current year 6.39
Extreme 6.39
26.95
1 year 3.55
Extreme 3.55
26.95
3 years 1.05
Extreme 1.05
26.95
5 years 0.61
Extreme 0.607
26.95
10 years 0.61
Extreme 0.607
26.95
Manager TitleAgeSince
Chief Executive Officer 74 01/02/2014
Director of Finance/CFO 71 01/11/2014
Chief Operating Officer - 01/01/2021
Director TitleAgeSince
Director/Board Member 66 01/11/2014
Chairman 74 27/01/2014
Director/Board Member 65 03/01/2017
Date Insider Type Main position Quantity % Market Cap.
18/05Buy

Chief Executive Officer

6,932 0.0082%
23/04Free

Director

30,000 0.0357%
28/01Fiscal year

Founder

4,20,000 0.5624%
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%-3.79%+162.59%+211.73% 94Cr
-0.53%+1.14%-13.86%-11.53% 4.37TCr
-3.58%-7.56%+243.47%+464.57% 3.07TCr
-2.19%+0.07%+14.02%-11.82% 3.04TCr
-1.70%-5.52%+0.07%+22.02% 2.93TCr
-1.59%-6.51%+8.30%+13.51% 2.42TCr
-0.23%+3.31%+52.25%+124.06% 1.33TCr
-1.61%-3.23% - - 1.3TCr
-0.18%+0.40%+9.53%+9.64% 1.32TCr
-1.69%-0.68%+99.02%+80.37% 1.21TCr
Average -1.34%-1.46%+63.93%+100.28% 2.11TCr
Weighted average by Cap. -1.59%-1.70%+48.84%+87.46%

Financials

2026 *2027 *
Net sales - 56.82L 49.18L 45.34L 42.41L 79.14L 54Cr 80.92L 5.39Cr 2.09Cr 26Cr 2.13Cr 2.09Cr 91Cr
Net income -6.4Cr -5.54Cr -5.11Cr -4.78Cr -8.92Cr -609.76Cr -9.12Cr -61Cr -24Cr -295.3Cr -24Cr -24Cr -1.03TCr -8.2Cr -7.1Cr -6.54Cr -6.12Cr -11Cr -781.4Cr -12Cr -78Cr -30Cr -378.42Cr -31Cr -30Cr -1.32TCr
Net Debt -20Cr -18Cr -16Cr -15Cr -28Cr -1.93TCr -29Cr -192.33Cr -75Cr -936.08Cr -76Cr -75Cr -3.26TCr -29Cr -25Cr -23Cr -22Cr -40Cr -2.76TCr -41Cr -274.48Cr -106.45Cr -1.34TCr -108.69Cr -106.36Cr -4.65TCr
Logo Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Employees
37
Date Price Change Volume
10/26/10 11.16 $ -0.09% 15,06,905
09/26/09 11.17 $ +0.18% 16,24,198
08/26/08 11.15 $ +0.27% 9,15,717
05/26/05 11.12 $ -5.12% 11,82,143
04/26/04 11.72 $ +1.03% 8,07,127
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
11.16USD
Average target price
33.33USD
Spread / Average Target
+198.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRVS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!